257 related articles for article (PubMed ID: 31694905)
1. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
[TBL] [Abstract][Full Text] [Related]
2. The Anti-Warburg Effect Elicited by the cAMP-PGC1α Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes.
Xing F; Luan Y; Cai J; Wu S; Mai J; Gu J; Zhang H; Li K; Lin Y; Xiao X; Liang J; Li Y; Chen W; Tan Y; Sheng L; Lu B; Lu W; Gao M; Qiu P; Su X; Yin W; Hu J; Chen Z; Sai K; Wang J; Chen F; Chen Y; Zhu S; Liu D; Cheng S; Xie Z; Zhu W; Yan G
Cell Rep; 2017 Jan; 18(2):468-481. PubMed ID: 28076790
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models.
Nguyen TTT; Zhang Y; Shang E; Shu C; Torrini C; Zhao J; Bianchetti E; Mela A; Humala N; Mahajan A; Harmanci AO; Lei Z; Maienschein-Cline M; Quinzii CM; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
J Clin Invest; 2020 Jul; 130(7):3699-3716. PubMed ID: 32315286
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma.
Nguyen TTT; Shang E; Shu C; Kim S; Mela A; Humala N; Mahajan A; Yang HW; Akman HO; Quinzii CM; Zhang G; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2021 Sep; 12(1):5203. PubMed ID: 34471141
[TBL] [Abstract][Full Text] [Related]
5. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
[TBL] [Abstract][Full Text] [Related]
6. VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.
Guo M; Zhang J; Han J; Hu Y; Ni H; Yuan J; Sun Y; Liu M; Gao L; Liao W; Ma C; Liu Y; Li S; Li N
J Transl Med; 2024 May; 22(1):419. PubMed ID: 38702818
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
9. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
10. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.
Pike LS; Smift AL; Croteau NJ; Ferrick DA; Wu M
Biochim Biophys Acta; 2011 Jun; 1807(6):726-34. PubMed ID: 21692241
[TBL] [Abstract][Full Text] [Related]
12. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
13. Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Tan Q; Yan X; Song L; Yi H; Li P; Sun G; Yu D; Li L; Zeng Z; Guo Z
Med Sci Monit; 2017 Aug; 23():4117-4125. PubMed ID: 28842551
[TBL] [Abstract][Full Text] [Related]
14. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
15. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project
Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
17. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
